

## CONTENTS

List of Abbreviations	6
<b>Chapter 1</b> General Introduction	7
<b>Chapter 2</b> Measuring Inflammatory Activity	25
2.1 The Distribution of New Enhancing Lesion Counts in Multiple Sclerosis: Further Explorations	27
2.2 T2w Subtraction MR Imaging in Phase II MS Trials: A Powerful New Outcome Measure	43
2.3 Cumulative Enhancing Lesion Volume as Outcome Measure in MS Clinical Trials	63
<b>Chapter 3</b> Measuring Neuroprotection and Neurorepair	77
3.1 Persistent T1 Hypointensity as an MRI Marker for Treatment Efficacy in Multiple Sclerosis	79
3.2 Cerebral Atrophy as Outcome Measure in Short-term Phase 2 Clinical Trials in Multiple Sclerosis	93
3.3 Lesional Magnetization Transfer Ratio – a Feasible Outcome for Remyelinating Treatment Trials in MS	107
<b>Chapter 4</b> General Discussion, Summary, and Future Perspectives	127
<b>Chapter 5</b> Summary in Dutch (Nederlandse samenvatting)	145
Dankwoord	151
Curriculum Vitae	157